260 related articles for article (PubMed ID: 34844247)
21. Des-gamma-carboxyprothrombin for early identification and prognosis of hepatocellular carcinoma--a case control study from western Nepal.
Mittal A; Gupta SP; Sathian B; Sreedharan J; Poudel B; Yadav SK; Pandeya DR
Asian Pac J Cancer Prev; 2012; 13(11):5773-5. PubMed ID: 23317255
[TBL] [Abstract][Full Text] [Related]
22. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
23. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
24. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.
Li J; Yang S; Li Y; Li C; Xia Y; Zhu S; Xia J
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1295-1303. PubMed ID: 35835873
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis.
Risaliti M; Bartolini I; Campani C; Arena U; Xodo C; Adotti V; Rosi M; Taddei A; Muiesan P; Amedei A; Batignani G; Marra F
World J Gastroenterol; 2022 Aug; 28(29):3981-3993. PubMed ID: 36157535
[TBL] [Abstract][Full Text] [Related]
26. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
27. Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
Gu J; Zhang X; Cui R; Zhang J; Wang Z; Jia Y; Miao R; Dong Y; Ma X; Fan H; Wang H; Ren L; Li Y; Niu W; Zhang J; Qu K; Liu C
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):836-844. PubMed ID: 30614882
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.
Sacco R; Bertini M; Petruzzi P; Bertoni M; Bargellini I; Bresci G; Federici G; Gambardella L; Metrangolo S; Parisi G; Romano A; Scaramuzzino A; Tumino E; Silvestri A; Altomare E; Vignali C; Capria A
World J Gastroenterol; 2009 Apr; 15(15):1843-8. PubMed ID: 19370781
[TBL] [Abstract][Full Text] [Related]
29. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
[TBL] [Abstract][Full Text] [Related]
30. Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A.
Ryu T; Takami Y; Wada Y; Tateishi M; Matsushima H; Mikagi K; Saitsu H
J Gastrointest Surg; 2017 Jun; 21(6):957-966. PubMed ID: 28299619
[TBL] [Abstract][Full Text] [Related]
31. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
32. A Clinical Scoring System for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma Within the Milan Criteria.
Ryu T; Takami Y; Wada Y; Tateishi M; Hara T; Yoshitomi M; Momosaki S; Yasumori K; Saitsu H; Okuda K
J Gastrointest Surg; 2019 Apr; 23(4):779-787. PubMed ID: 30788712
[TBL] [Abstract][Full Text] [Related]
33. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.
Farinati F; Vanin V; Giacomin A; Pozzan C; Cillo U; Vitale A; Di Nolfo AM; Del Poggio P; Benvegnu' L; Rapaccini G; Zoli M; Borzio F; Giannini EG; Caturelli E; Trevisani F;
Liver Int; 2015 Jan; 35(1):223-31. PubMed ID: 25074434
[TBL] [Abstract][Full Text] [Related]
34. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
[No Abstract] [Full Text] [Related]
35. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma.
Wang SY; Su TH; Chen BB; Liu CJ; Liu CH; Yang HC; Tseng TC; Chen PJ; Kao JH
J Formos Med Assoc; 2022 Aug; 121(8):1579-1587. PubMed ID: 35078686
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Zhang JB; Chen Y; Zhang B; Xie X; Zhang L; Ge N; Ren Z; Ye SL
Eur J Gastroenterol Hepatol; 2011 Sep; 23(9):787-93. PubMed ID: 21730869
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.
Park Y; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yeon JE; Byun KS; Kim HS; Kim JH; Kim SU
BMC Cancer; 2019 Apr; 19(1):363. PubMed ID: 30991968
[TBL] [Abstract][Full Text] [Related]
39. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma.
Liu G; Ouyang Q; Xia F; Fan G; Yu J; Zhang C; Wang D
HPB (Oxford); 2019 Jan; 21(1):107-113. PubMed ID: 30017783
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan.
Hiraoka A; Michitaka K; Kumada T; Izumi N; Kadoya M; Kokudo N; Kubo S; Matsuyama Y; Nakashima O; Sakamoto M; Takayama T; Kokudo T; Kashiwabara K; Eguchi S; Yamashita T; Kudo M
Liver Cancer; 2019 Oct; 8(5):403-411. PubMed ID: 31768348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
